Meta Pixel

News and Announcements

HealthTech announces acceptance into the government-backed MDPP

  • Published April 29, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

“MDPP has been incredibly valuable to Peak Medical, building and validating an MVP, giving access to Peak Medical to work with world class researchers and engineers. It is a rigorous expert panel process to get into the program, with due diligence done on Peak Medical by the government and university supported program”. Hayley Saddington.

MTPConnect has launched a new program with industry partners this year supporting early clinical development of medical devices. The Clinical Translation and Commercialisation – Medtech (CTCM) program is a $19.75 million initiative funded by the Federal Government’s Medical Research Future Fund and will offer financial assistance, educational support and infrastructure access to Australian small to medium-sized enterprises (SMEs). The Medical Device Partnering Program (led by Flinders University) is proud to be announced as a partner on the program.  The other partners are the Medical Technology Association of Australia, Cicada Innovations, the BridgeTech Program and Therapeutic Innovation Australia. This is an exciting and advantageous ecosystem for Peak Medical to be supported by.

MDPP Director Professor Karen Reynolds said: “MDPP has a 13-year track record of supporting medical device ventures across the innovation life cycle, from ideation to product development to commercialisation. We’re delighted to now join MTPConnect and other partners to deliver the new CTCM program, leveraging our capabilities and extensive networks to assist Australian SMEs achieve key clinical milestones and accelerate the adoption and commercialisation of new devices.”

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now